Abstract:Replication stress, a major cause of genome instability in cycling cells, is mainly prevented by the ATR-dependent replication stress response pathway in somatic cells. However, the replication stress response pathway in embryonic stem cells (ESCs) may be different due to alterations in cell cycle phase length. The transcription factor MYBL2, which is implicated in cell cycle regulation, is expressed a hundred to a thousand-fold more in ESCs compared with somatic cells. Here we show that MYBL2 activates ATM an… Show more
“…What is unique in naïve pluripotent cells is the ease in which cultures activate Atm and slide into replication catastrophe when faced with a replication challenge. Considering this finding, it is not surprising that Atm was recently observed to play a prominent role in the replication stress response of naïve mESC cultures (Blakemore et al, 2021). In agreement, Atr deletion is lethal after E4.5, during a later developmental window than blastocyst-derived mESCs, and consistent with a less prominent role for Atr during naïve pluripotency (de Klein et al, 2000).…”
Section: Discussionmentioning
confidence: 91%
“…This includes H2ax phosphorylation and remodelled replication forks protected by Rad51 (Ahuja et al, 2016). Atr is implicated in somatic replication fork remodelling and protection (Berti et al, 2020), and inhibiting Atr reduces replication rates (Blakemore et al, 2021) and partially supresses spontaneous γ-H2ax (Ahuja et al, 2016) in mESC cultures. Additionally, we observe Atr-dependent Chek1 phosphorylation in HU treated mESCs.…”
SummaryReplication stress is an endemic threat to genome stability. For reasons unknown, replication stress response factors become essential during peri-implantation development. This coincides with a stem cell potency switch from the naïve to the primed state. Using genetically matched, chimera-derived mouse naïve embryonic (mESC) and primed epiblast stem cells (mEpiSC) we found that replication stress management differs between potency states. Primed mEpiSCs rely on Atr activity to prevent replication catastrophe, minimize genomic damage, avoid apoptosis, and re-enter the cell cycle. Conversely, under replications stress, mESCs readily activate Atm regardless of Atr activity, undergo replication catastrophe, and induce apoptosis. Primed pluripotent cells therefore engage Atr to counteract replication difficulties and maintain viability, whereas cells in the naïve state are more readily cleared under the same conditions. We anticipate these divergent strategies enable pluripotent cells of different potency states to meet associated proliferative or developmental demands during early development.
“…What is unique in naïve pluripotent cells is the ease in which cultures activate Atm and slide into replication catastrophe when faced with a replication challenge. Considering this finding, it is not surprising that Atm was recently observed to play a prominent role in the replication stress response of naïve mESC cultures (Blakemore et al, 2021). In agreement, Atr deletion is lethal after E4.5, during a later developmental window than blastocyst-derived mESCs, and consistent with a less prominent role for Atr during naïve pluripotency (de Klein et al, 2000).…”
Section: Discussionmentioning
confidence: 91%
“…This includes H2ax phosphorylation and remodelled replication forks protected by Rad51 (Ahuja et al, 2016). Atr is implicated in somatic replication fork remodelling and protection (Berti et al, 2020), and inhibiting Atr reduces replication rates (Blakemore et al, 2021) and partially supresses spontaneous γ-H2ax (Ahuja et al, 2016) in mESC cultures. Additionally, we observe Atr-dependent Chek1 phosphorylation in HU treated mESCs.…”
SummaryReplication stress is an endemic threat to genome stability. For reasons unknown, replication stress response factors become essential during peri-implantation development. This coincides with a stem cell potency switch from the naïve to the primed state. Using genetically matched, chimera-derived mouse naïve embryonic (mESC) and primed epiblast stem cells (mEpiSC) we found that replication stress management differs between potency states. Primed mEpiSCs rely on Atr activity to prevent replication catastrophe, minimize genomic damage, avoid apoptosis, and re-enter the cell cycle. Conversely, under replications stress, mESCs readily activate Atm regardless of Atr activity, undergo replication catastrophe, and induce apoptosis. Primed pluripotent cells therefore engage Atr to counteract replication difficulties and maintain viability, whereas cells in the naïve state are more readily cleared under the same conditions. We anticipate these divergent strategies enable pluripotent cells of different potency states to meet associated proliferative or developmental demands during early development.
“…Consequently, loss of MYBL2 or inhibition of ATM in ESCs leads to replication fork slowing, increased replication fork stalling, and increased origin firing. This finding suggests that in addition to ATR-mediated DDR, a MYBL2-MRN-ATM replication stress response pathway in ESCs could be used to control DNA replication initiation and genome stability [ 51 ]. In addition, immunotherapeutic approaches would be promising to pursue, as a direct effect of ATR activity on programmed cell death 1 ligand (PD-L1) expression and stability has been observed since ATR inhibition results in down-regulation of PD-L1 protein levels [ 52 , 53 ].…”
Section: Adaptation Of Cscs To Replication Stressmentioning
Cancer stem cells (CSCs) are pluripotent and highly tumorigenic cells that can re-populate a tumor and cause relapses even after initially successful therapy. As with tissue stem cells, CSCs possess enhanced DNA repair mechanisms. An active DNA damage response alleviates the increased oxidative and replicative stress and leads to therapy resistance. On the other hand, mutations in DNA repair genes cause genomic instability, therefore driving tumor evolution and developing highly aggressive CSC phenotypes. However, the role of DNA repair proteins in CSCs extends beyond the level of DNA damage. In recent years, more and more studies have reported the unexpected role of DNA repair proteins in the regulation of transcription, CSC signaling pathways, intracellular levels of reactive oxygen species (ROS), and epithelial–mesenchymal transition (EMT). Moreover, DNA damage signaling plays an essential role in the immune response towards tumor cells. Due to its high importance for the CSC phenotype and treatment resistance, the DNA damage response is a promising target for individualized therapies. Furthermore, understanding the dependence of CSC on DNA repair pathways can be therapeutically exploited to induce synthetic lethality and sensitize CSCs to anti-cancer therapies. This review discusses the different roles of DNA repair proteins in CSC maintenance and their potential as therapeutic targets.
“…However, it is known that embryonic cell cycles and DNA replication are regulated somewhat differently than in somatic cells. For example, the stabilisation of CDT1 during DNA replication is not enough to induce re-replication in Xenopus laevis egg extract (14), as it is in human somatic cells (15); whilst origin firing is regulated by both ATM and ATR in embryonic stem cells, but mainly by ATR in somatic cells (16). Moreover, embryonic systems are known to maintain fast cell cycles with non-existent or short gap phases, with reduced regulation of cell cycle phase transition and accumulation of high levels of replication factors to sustain this fast proliferation rate.…”
To ensure faultless duplication of the entire genome, eukaryotic replication initiates from thousands of replication origins. Replication forks emanating from origins move through the chromatin until they encounter forks from neighbouring origins, at which point they terminate. In the final stages of this process the replication machinery (replisome) is unloaded from chromatin and disassembled. Work from model organisms has elucidated that during replisome unloading, the MCM7 subunit of the terminated replicative helicase is polyubiquitylated and processed by p97/VCP segregase, leading to disassembly of the helicase and the replisome, which is built around it. In higher eukaryotes (worms, frogs, mouse embryonic stem cells), MCM7 ubiquitylation is driven by a Cullin2-based ubiquitin ligase, with LRR1 as a substrate receptor. To date, most of our knowledge of replication termination comes from model organisms and embryonic systems and little is known about how this process is executed and regulated in human somatic cells. Here we thus established methods to study replisome disassembly in human model cell lines. Using flow cytometry, immunofluorescence microscopy and chromatin isolation with western blotting, we can visualise unloading of the replisome (MCM7 and CDC45) from chromatin by the end of S-phase. We observe interaction of replicative helicase (CMG complex) with CUL2LRR1 and ubiquitylation of MCM7 on chromatin, specifically in S-phase, suggesting that this is a replication-dependent modification. Importantly, we are able to show that replisome disassembly in this system also requires Cullin2, LRR1 and p97, demonstrating conservation of the mechanism. Moreover, we present evidence that the back-up mitotic replisome disassembly pathway is also recapitulated in human somatic cells. Finally, while we find that treatment with small molecule inhibitors against cullin-based ubiquitin ligases (CULi) and p97 (p97i) does lead to phenotypes of replisome disassembly defects, they also both lead to induction of replication stress in somatic cells, which limits their usefulness as tools to specifically target replisome disassembly processes in this setting.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.